Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Biotech firm Gilead Sciences has announced plans to voluntarily withdraw the US accelerated approval for Trodelvy ...

Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...

Confounding data from a Pfizer clinical trial have rattled the field of gene therapy for Duchenne muscular dystrophy ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, ...

US drugmakers Gilead Sciences (Nasdaq: GILD) and Merck & Co (NYSE: MRK) have announced new results from a Phase II clinical ...